+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global End Stage Renal Disease Market (2022-2027) by Treatment & Diagnosis, End User, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon


  • 181 Pages
  • October 2022
  • Region: Global
  • Infogence Global Research
  • ID: 5684377

10% of the Worldwide Population is Affected by End Stage Renal Disease, and Millions Die Each Year as They Do Not Have Access to Affordable Treatment

The Global End Stage Renal Disease Market is estimated to be USD 38.66 Bn in 2022 and is expected to reach USD 73.37 Bn by 2027, growing at a CAGR of 13.67%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the Global End Stage Renal Disease Market stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

The Global End Stage Renal Disease Market is segmented based on Treatment & Diagnosis, End User, and Geography.
  • By Treatment & Diagnosis, the market is classified into Treatment and Diagnosis.
  • By End User, the market is classified into Dialysis Centers, Hospital & Clinics, and Research & Academic Institutes.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Abbott Laboratories, Amgen Inc., Asahi Kasei Medical Co., Ltd., AstraZeneca, Novartis Ag, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global End Stage Renal Disease Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

The analyst analyses the Global End Stage Renal Disease Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global End Stage Renal Disease Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst's competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global End Stage Renal Disease Market

What is the estimated value of the Global End Stage Renal Disease Market?

The Global End Stage Renal Disease Market was estimated to be valued at $38.66 Billion in 2022.

What is the growth rate of the Global End Stage Renal Disease Market?

The growth rate of the Global End Stage Renal Disease Market is 13.6%, with an estimated value of $73.37 Billion by 2027.

What is the forecasted size of the Global End Stage Renal Disease Market?

The Global End Stage Renal Disease Market is estimated to be worth $73.37 Billion by 2027.

Who are the key companies in the Global End Stage Renal Disease Market?

Key companies in the Global End Stage Renal Disease Market include Abbott Laboratories, Amgen Inc., Asahi Kasei Medical Co., Ltd., AstraZeneca PLC, B. Braun Melsungen Ag, Baxter International, Inc., Becton, Dickinson and Company, Bristol and Cantel Medical Corp..

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Proliferation in the Number of Chronic Kidney Diseases
4.1.2 Growing Geriatric Population with Hypertension & Diabetes
4.1.3 Increasing Lifestyle Changes, Including Smoking, Drinking, and Consumption of Processed Food
4.2 Restraints
4.2.1 Stringent Regulatory Protocols for Dialysis Products
4.2.2 High Cost Associated With the Treatment
4.3 Opportunities
4.3.1 Rising Introduction of New Technologically Enhanced Products
4.3.2 Increasing Research & Development Investment Coupled with Collaborations Among Hospitals
4.4 Challenges
4.4.1 Risk of Complications During Surgery
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global End Stage Renal Disease Market, By Treatment and Diagnosis
6.1 Introduction
6.2 Treatment
6.2.1 Dialysis Hemodialysis Peritoneal Dialysis Wearable Artificial Kidney
6.2.2 Transplantation
6.3 Diagnosis
6.3.1 Blood Tests
6.3.2 Imaging Tests
6.3.3 Kidney Sample Removal for Testing
6.3.4 Urine Tests
7 Global End Stage Renal Disease Market, By End User
7.1 Introduction
7.2 Dialysis Centers
7.3 Hospital & Clinics
7.4 Research and Academic Institutes
8 Americas’ End Stage Renal Disease Market
8.1 Introduction
8.2 Argentina
8.3 Brazil
8.4 Canada
8.5 Chile
8.6 Colombia
8.7 Mexico
8.8 Peru
8.9 United States
8.10 Rest of Americas
9 Europe’s End Stage Renal Disease Market
9.1 Introduction
9.2 Austria
9.3 Belgium
9.4 Denmark
9.5 Finland
9.6 France
9.7 Germany
9.8 Italy
9.9 Netherlands
9.10 Norway
9.11 Poland
9.12 Russia
9.13 Spain
9.14 Sweden
9.15 Switzerland
9.16 United Kingdom
9.17 Rest of Europe
10 Middle East and Africa’s End Stage Renal Disease Market
10.1 Introduction
10.2 Egypt
10.3 Israel
10.4 Qatar
10.5 Saudi Arabia
10.6 South Africa
10.7 United Arab Emirates
10.8 Rest of MEA
11 APAC’s End Stage Renal Disease Market
11.1 Introduction
11.2 Australia
11.3 Bangladesh
11.4 China
11.5 India
11.6 Indonesia
11.7 Japan
11.8 Malaysia
11.9 Philippines
11.10 Singapore
11.11 South Korea
11.12 Sri Lanka
11.13 Thailand
11.14 Taiwan
11.15 Rest of Asia-Pacific
12 Competitive Landscape
12.1 Competitive Quadrant
12.2 Market Share Analysis
12.3 Strategic Initiatives
12.3.1 M&A and Investments
12.3.2 Partnerships and Collaborations
12.3.3 Product Developments and Improvements
13 Company Profiles
13.1 Abbott Laboratories
13.2 Amgen Inc.
13.3 Asahi Kasei Medical Co., Ltd.
13.4 AstraZeneca PLC
13.5 B. Braun Melsungen Ag
13.6 Baxter International, Inc.
13.7 Becton, Dickinson and Company
13.8 Bristol-Myers Squibb Co.
13.9 Cantel Medical Corp.
13.10 Davita Healthcare Partners Inc.
13.11 Fresenius Medical Care Ag & Co. KGaA
13.12 GSK PLC
13.13 JMS Co. Ltd.
13.14 Keryx Biopharmaceuticals, Inc.
13.15 Kissei Pharmaceutical Co., Ltd.
13.16 Medtronic PLC
13.17 Nikkiso Co., Ltd.
13.18 Novartis Ag
13.19 Pfizer Inc.
13.20 Roche Ltd.
13.21 Sanofi SA
13.22 Teva Pharmaceutical Industries Ltd.
14 Appendix
14.1 Questionnaire

Companies Mentioned

  • Abbott Laboratories
  • Amgen Inc.
  • Asahi Kasei Medical Co., Ltd.
  • AstraZeneca PLC
  • B. Braun Melsungen Ag
  • Baxter International, Inc.
  • Becton, Dickinson and Company
  • Bristol-Myers Squibb Co.
  • Cantel Medical Corp.
  • Davita Healthcare Partners Inc.
  • Fresenius Medical Care Ag & Co. KGaA
  • JMS Co. Ltd.
  • Keryx Biopharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Medtronic PLC
  • Nikkiso Co., Ltd.
  • Novartis Ag
  • Pfizer Inc.
  • Roche Ltd.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.